Moleculin Biotech shares surge 11.27% after hours as independent study confirms no cardiotoxicity in 90 subjects.

Moleculin Biotech (MBRX) surged 11.27% in after-hours trading following an independent assessment confirming no cardiotoxicity of its drug candidate Annamycin in 90 subjects. This development addresses a critical safety concern for the therapy, potentially accelerating regulatory pathways and investor confidence. The announcement, reported by GlobeNewswire eight days prior, aligns with the company’s ongoing pivotal "MIRACLE" Phase 3 trial for acute myeloid leukemia and its broader clinical expansion. Additional recent updates, including global trial expansion and externally funded research, further reinforced the stock’s positive momentum. The after-hours rally reflects renewed optimism about Annamycin’s safety profile and Moleculin’s progress in advancing its pipeline.